advertisement
Abstract #24262 Published in IGR 11-3
Comparison of morning versus evening dosing and 24-h post-dose efficacy of travoprost compared with latanoprost in patients with open-angle glaucoma
Yan DB; Battista RA; Haidich A-B; Konstas AGPCurrent Medical Research and Opinion 2008; 24: 3023-3027
OBJECTIVE: To compare the IOP-lowering efficacy of a.m.-dosed travoprost and latanoprost at 24-h post-dose. Research design and methods: Open-angle glaucoma patients not naive to prostaglandin therapy and currently controlled on p.m.-dosed (2100) latanoprost (n=21) or travoprost (n=30) had baseline IOPs measured at 0900. In a randomized, single-masked, crossover design, patients received travoprost (Travatany) or latanoprost (Xalatanz) at 0900 for 4 weeks, then were crossed over to receive the second prostaglandin for another 4 weeks. Treatment IOP was measured at 0900 prior to morning dose at both 4 and 8 week visits. Patient dosing preference (a.m./p.m.) was surveyed on exit. Main outcome measure: Intraocular pressure (IOP). RESULTS: The mean IOP in the first period when all patients were dosed in the evening was assessed 12 h after dosing at 09:00 and it was similar in the two treatment groups (mean ±standard deviation: 17.9 ±2.7 mmHg for travoprost versus 17.7±2.5 mmHg for latanoprost, p=0.812). In the a.m.-dosing crossover comparison, the 24-h post-dose IOP was significantly lower ( p < 0.001) on travoprost (16.9 ±3.1 mmHg) compared to latanoprost (18.6±3.3 mmHg). In the exit survey, 51% of patients preferred a.m.-dosing. CONCLUSIONS: a.m.-dosed travoprost is superior to a.m.-dosed latanoprost by 1.7 mmHg at 24-h post-dose.
Dr. D.B. Yan, Ophthalmic Consultant Centres, 1880 Sismet Road, Mississauga, ON L4W 1W9, Canada. d.yan@sympatico.ca
Classification:
11.4 Prostaglandins (Part of: 11 Medical treatment)
